FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Vashington, | D.C. | 20549 |
|-------------|------|-------|

| STATEMENT | OF | CHANGES | IN BEN | IEFICIAL | OWNERSHIP |
|-----------|----|----------------|--------|----------|------------------|
| | | | | | |

| OMB APPROVAL | | | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0 | | | | | | | | | | |
| Estimated average burden | | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* DeLong Mark Jeffrey | | | | | | 2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [APLS] | | | | | | | (Ched | ck all applica | tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owne Officer (give title below) Senior Vice President | | 10% Ov | ner | |
|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-------------|-----------------|-------------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|------|---------------------------------------------------------------|-----------------------------------------------|------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------|--------------------------------------------------------------------------|---------------------------------------|
| (Last) (First) (Middle) C/O APELLIS PHARMACEUTICALS, INC. | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 01/21/2022 | | | | | | | | - X | | | below) | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | |
| 100 5TH AVENUE, 3RD FLOOR (Street) | | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) 01/25/2022 | | | | | | 6. Ind | Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| WALTH | AM M | IA | 02451 | | | | | | | | | X | Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| (City) | (S | tate) | (Zip) | | | | | | | | | | | | 1 613011 | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date) | | | | Execution Date, | | 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) (Disposed Of (D) (Instr. 3, 4) | | | | 5. Amour Securitie Beneficia Owned F | es Fo ally (D) Following (I) | | Form: Direct D) or Indirect I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | | |
| | | | | | | | | Code | v | Amount (A) or (D) | | or | Price | Transacti | Transaction(s) (Instr. 3 and 4) | | | (IIIsu. 4) | |
| Common Stock 01/21. | | | | 1/202 | 22 | | | A | | 13,913 ⁽¹⁾⁽²⁾ A | | \$0.00 | 24,285 | | | D | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| Derivative Conversion Date | | 3. Transaction Date (Month/Day/Year) | Execution D | | 4. Transa Code (I 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable an Expiration Date (Month/Day/Year) | | te | 7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4) | | curity | 8. Price of Derivative Security (Instr. 5) | 9. Numbe derivative Securities Beneficial Owned Following Reported Transactio | e s Illy | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) |
| | | | | | Code | v | (A) | (D) | Date Exercisa | able | Expiration Date | Title | | mount r umber f hares | | (Instr. 4) | on(s) | | |
| Stock Option (right to buy) | \$35.46 | 01/21/2022 | | | A | | 19,735 ⁽⁴⁾ | | (3) | | 01/20/2032 | Commo | | 9,735 | \$0.00 | 19,73 | 5 | D | |

Explanation of Responses:

- 1. This represents a restricted stock unit grant made on January 21, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service.
- 2. On January 23, 2021, the reporting person filed a Form 4 that inadvertently reported that the reporting person was granted a restricted stock unit of 10,952 shares. This amendment is being filed solely to correct such number of shares to 13,913.
- 3. This represents a non-qualified stock option grant made on January 21, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.
- 4. On January 23, 2021, the reporting person filed a Form 4 that inadvertently reported that the reporting person was granted a non-qualified stock option grant of 15,024 shares. This is amendment is being filed solely to correct such number of shares to 19,735.

Remarks:

/s/ David Watson, attorney-in-

** Signature of Reporting Person

<u>fact</u>

02/07/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.